Alnylam Pharmaceuticals, INC Form 4 insider transactions

Director Dennis A. Ausiello reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Director Michael W. Bonney reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Director Olivier Brandicourt reports acquisition of common stock and stock options in Alnylam Pharmaceuticals.

Director Margaret A. Hamburg reports the acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Director Peter Kellogg reports the acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Director Carolyn R. Bertozzi reports the acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

CEO Yvonne Greenstreet reports a gift transfer of Alnylam Pharmaceuticals stock for estate planning and acquisition of shares through the company's 401(k) plan.

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, reports stock sales and option exercises under a pre-arranged trading plan.

Director David E.I. Pyott exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Amy Schulman, a director at Alnylam Pharmaceuticals, exercised stock options to acquire 2,750 shares of common stock at a price of $131.21 on March 13, 2025.

Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, reports the acquisition of restricted stock units and the sale of common stock to cover tax obligations.

Robert W. Hesslein, EVP, CLO and Secretary of Alnylam Pharmaceuticals, reports acquisition of common stock and stock options.

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reports the acquisition and disposition of company stock and stock options.

CMO & EVP Dev & Med Affairs Pushkal Garg reports acquisition of restricted stock units and sales of Alnylam Pharmaceuticals (ALNY) common stock, including transactions under a 10b5-1 trading plan.

Jeffrey V. Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reports acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet sold shares of common stock on February 28, 2025, to cover tax obligations related to vesting restricted stock units.

EVP and CFO of Alnylam Pharmaceuticals, Jeffrey V. Poulton, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, Tolga Tanguler, reports the sale of company stock to cover tax obligations after restricted stock units vested.

CMO & EVP Dev & Med Affairs Pushkal Garg reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, sold shares of common stock on February 28, 2025, to cover tax obligations arising from the vesting of restricted stock units.

Alnylam Pharmaceuticals' CEO, Yvonne Greenstreet, reports acquisition and disposal of company stock, including shares from vested performance-based stock units and sales to cover tax obligations.

Jeffrey V. Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports acquisition and disposal of company stock, including shares from vested performance-based stock units and sales to cover tax obligations.

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reports the vesting of performance-based stock units and subsequent sales of common stock to cover tax obligations and under a pre-arranged trading plan.

CMO of Alnylam Pharmaceuticals, Pushkal Garg, reports acquisition and disposal of company stock, including sales to cover tax obligations and transactions under a 10b5-1 trading plan.

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Phillip A. Sharp exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Pushkal Garg, CMO & EVP of Development and Medical Affairs at Alnylam Pharmaceuticals, sold 1,743 shares of common stock on December 12, 2024, under a pre-arranged 10b5-1 trading plan.

Alnylam Pharmaceuticals CEO, Yvonne Greenstreet, sold a portion of her shares following the vesting of a performance-based stock unit, triggered by a positive clinical trial result and FDA acceptance of a new drug application.

Alnylam Pharmaceuticals' Chief Medical Officer, Pushkal Garg, sold a portion of his shares following the vesting of a performance-based stock unit.